Drug
Navlimetostat
Navlimetostat: highest development phase Phase 2, developed by Bristol-Myers Squibb. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bristol-Myers Squibb
Trials
| Drug | Phase | Indication |
|---|---|---|
| Navlimetostat NCT07492680 | Phase 2 | Solid Tumors |
| Navlimetostat NCT07777133 | Phase 1 |
Latest
No recent events.
Follow Navlimetostat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.